Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. April 2022 07:33 ET | Quelle: Immuron Limited

Immuron new MTEC project proposal “Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease”

Key Highlights: Immuron’s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award’Travelan Investigational New Drug (IND)...
15. April 2019 09:00 ET | Quelle: Immuron Limited

Immuron sales surge by 66% in the Third Quarter of FY19

Key Highlights: Immuron achieved 66% YoY growth in worldwide sales for the third quarter of FY19, ending March 31, 2019.In Australia Q3 sales of Travelan® surged ahead, growing 73% YoY.In the US Q3...
11. April 2019 09:00 ET | Quelle: Immuron Limited

Immuron Aims to Secure FDA Approval for IMM-124E to Prevent Travelers’ Diarrhea

Key Points Immuron to develop U.S. registration dossier for IMM-124E for Travelers’ DiarrheaCompany anticipates significant inflection in sales with successful FDA registration of IMM-124ECompany to...